Fairborn, OH, United States of America

Anthony R Arment

This inventor holds 9 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Pop Test Oncology, LLC, Other. Active years: 2017-2025.

USPTO Granted Patents = 9 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 6

Forward Citations = 56(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Anthony R. Arment

Introduction

Anthony R. Arment is a notable inventor based in Fairborn, Ohio, with a significant portfolio of nine patents. His work primarily focuses on pharmaceutical compositions and methods that address critical health issues.

Latest Patents

Among his latest patents, one invention relates to the use of cortisol blockers, specifically glucocorticoid receptor antagonists, for treating or preventing viral infections, treatment-resistant prostate cancer, neoplasia, and infections related to acute or chronic injury or disease. Another patent provides therapeutic agents and methods that utilize glucocorticoid receptor antagonists for the treatment of infection, neoplasia, and fatty liver disease.

Career Highlights

Throughout his career, Anthony has made significant strides in the field of pharmaceuticals. His innovative approaches have the potential to impact various medical conditions, showcasing his dedication to advancing healthcare solutions.

Collaborations

Anthony has collaborated with notable professionals in his field, including Andreas J. Kesel and Myron C. Rapkin. Their combined expertise contributes to the development of groundbreaking treatments.

Conclusion

Anthony R. Arment's contributions to pharmaceutical innovations highlight his commitment to improving health outcomes through his inventive work. His patents reflect a deep understanding of complex medical challenges and a drive to find effective solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…